NCT04985604 - Tovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 15, 2021

Primary Completion Date

July 8, 2024

Study Completion Date

July 8, 2024

Conditions

MelanomaSolid TumorCRAF Gene AmplificationRAF1 Gene AmplificationBRAF Gene FusionBRAF FusionCRAF Gene FusionCRAF FusionRAF1 Gene FusionRAF1 FusionThyroid Cancer, PapillarySpitzoid MelanomaPilocytic AstrocytomaPilocytic Astrocytoma, AdultNon Small Cell Lung CancerNon-Small Cell AdenocarcinomaColorectal CancerPancreatic Acinar CarcinomaSpitzoid Malignant MelanomaBladder CancerBladder Urothelial CarcinomaMAP Kinase Family Gene MutationRAF Mutation

Interventions

DRUG

Tovorafenib

Tovorafenib tablet for oral use.

Trial Locations (20)

15213

UPMC Hillman Cancer Center, Pittsburgh

32256

Cancer Specialists of North Florida, Jacksonville

37232

Vanderbilt-Ingram Cancer Center, Nashville

46250

Community North Cancer Center, Indianapolis

80045

University of Colorado Hospital, Aurora

90025

The Angeles Clinic, Los Angeles

92663

Hoag Health, Newport Beach

97239

OHSU Knight Cancer Institute, Portland

Unknown

Monash Medical Centre, Clayton

Antwerp University Hospital, Edegem

Princess Margaret Cancer Centre, Toronto

The Hospital for Sick Children, Toronto

Hopital de La Timone - APHM, Marseille

Dong-A University Hospital, Busan

Asan Medical Center, Seoul

Samsung Medical Center, Seoul

Severance Hospital, Yonsei University Health System, Seoul

Hospital Clinic Barcelona, Barcelona

Hospital Universitari Vall d'Hebron, Barcelona

Hospital Universitario Ramón y Cajal, Madrid